Innovent Biologics revenue and financials
In the fiscal year ended December 2025, Innovent Biologics reported revenue of ¥13.04B (+38.42% year over year). Net income was ¥813.57M, a net margin of 6.2%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +38.42%
- 2025 vs 2024
- Net margin
- 6.2%
- 2024: -1.0%
How Innovent Biologics is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 27.7% a year on average over the last 5 years
Compound annual growth rate: from ¥3.84B in 2020 to ¥13.04B in 2025.
Revenue has grown for 7 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin rose from −68.5% to 5.6%
Operating income over revenue, 2022 → 2025: 74.2 percentage points.
Shares outstanding up 28.3% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 1 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 13,042 | 9,422 | 6,206 | 4,556 | 4,270 | 3,844 | 1,048 | 9.5 | 75.0 | 28.8 |
| Cost of revenue | 3,044 | 2,258 | 1,807 | 1,382 | 1,224 | 772 | 625 | — | — | — |
| Gross profit | 9,998 | 7,163 | 4,399 | 3,175 | 3,045 | 3,072 | 423 | 9.5 | 75.0 | 28.8 |
| Selling, general and administrative | 6,640 | 5,085 | 3,851 | 3,426 | 3,426 | 1,778 | 948 | 356 | 87.8 | 57.4 |
| Research and development | 2,624 | 2,202 | 2,112 | 2,871 | 2,323 | 1,851 | 1,295 | 1,222 | 612 | 385 |
| Operating income | 734 | -123 | -1,564 | -3,123 | -2,703 | -557 | -1,820 | -1,569 | -625 | -413 |
| EBIT | 734 | -123 | -1,564 | -3,123 | -2,703 | -557 | -1,820 | -1,569 | -625 | -413 |
| EBITDA | 1,310 | 263 | -1,288 | -2,878 | -2,538 | -489 | -1,746 | -1,506 | -565 | -360 |
| Interest expense | 79.6 | 67.6 | 98.6 | 102 | 62.5 | 68.4 | 59.5 | 69.0 | 57.2 | 53.8 |
| Pre-tax income | 839 | -78.6 | -1,144 | -2,170 | -2,642 | -859 | -1,720 | -5,873 | -716 | -544 |
| Income tax | 25.4 | 16.0 | -116 | 8.8 | 87.0 | 140 | — | — | — | — |
| Net income | 814 | -94.6 | -1,028 | -2,179 | -2,729 | -998 | -1,720 | -5,771 | -562 | -504 |
| Net income to common shareholders | 814 | -94.6 | -1,028 | -2,179 | -2,729 | -998 | -1,720 | -5,771 | -562 | -504 |
| Basic EPS | 0.48 | -0.06 | -0.66 | -1.46 | -1.87 | -0.74 | -1.46 | -17.24 | -5.96 | -6.57 |
| Diluted EPS | 0.47 | -0.06 | -0.66 | -1.46 | -1.88 | -0.74 | -1.46 | -17.24 | -5.96 | -6.57 |
| Average shares (basic) | 1,677 | 1,627 | 1,560 | 1,490 | 1,456 | 1,357 | 1,178 | 335 | 94.3 | 76.8 |
| Average shares (diluted) | 1,741 | 1,627 | 1,560 | 1,490 | 1,456 | 1,357 | 1,178 | 335 | 94.3 | 76.8 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 8,618 | 7,088 | 5,953 | 5,470 | 3,952 | 3,505 | 2,702 | 2,317 | 2,240 | 2,328 |
| Cost of revenue | 1,999 | 1,690 | 1,354 | 1,164 | 1,094 | 1,025 | 782 | 673 | 708 | 668 |
| Gross profit | 6,619 | 5,398 | 4,600 | 4,306 | 2,858 | 2,479 | 1,920 | 1,643 | 1,531 | 1,660 |
| Selling, general and administrative | 3,730 | 3,823 | 2,817 | 2,886 | 2,199 | 2,135 | 1,716 | 1,621 | 1,806 | 2,034 |
| Research and development | 1,684 | 1,615 | 1,009 | 1,111 | 1,091 | 1,189 | 923 | 1,697 | 1,174 | 1,348 |
| Operating income | 1,206 | -39.9 | 774 | 309 | -432 | -845 | -719 | -1,674 | -1,449 | -1,722 |
| EBIT | 1,206 | -39.9 | 774 | 309 | -432 | -845 | -719 | -1,674 | -1,449 | -1,722 |
| EBITDA | 1,523 | 281 | 1,030 | 511 | -249 | -742 | -547 | -1,534 | -1,344 | -1,634 |
| Interest expense | 40.9 | 18.3 | 61.3 | 29.6 | 38.0 | 48.3 | 50.3 | 57.1 | 44.6 | 35.4 |
| Pre-tax income | 1,612 | -58.2 | 897 | 314 | -393 | -888 | -256 | -1,172 | -999 | -1,638 |
| Income tax | 359 | -37.4 | 62.8 | 16.0 | 0.0 | 0.5 | -117 | 57.2 | -48.4 | 86.9 |
| Net income | 1,253 | -20.8 | 834 | 298 | -393 | -889 | -139 | -1,229 | -950 | -1,725 |
| Net income to common shareholders | 1,253 | -20.8 | 834 | 298 | -393 | -889 | -139 | -1,229 | -950 | -1,725 |
| Basic EPS | 0.73 | -0.01 | 0.51 | 0.18 | -0.24 | -0.56 | -0.09 | -0.81 | -0.65 | -1.18 |
| Diluted EPS | 0.70 | -0.01 | 0.49 | 0.18 | -0.24 | -0.56 | -0.09 | -0.81 | -0.65 | -1.19 |
| Average shares (basic) | 1,726 | 1,712 | 1,643 | 1,632 | 1,623 | 1,584 | 1,535 | 1,515 | 1,465 | 1,461 |
| Average shares (diluted) | 1,801 | 1,788 | 1,695 | 1,632 | 1,623 | 1,584 | 1,535 | 1,515 | 1,465 | 1,461 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 37,348 | 21,603 | 20,627 | 17,589 | 16,244 | 11,835 | 7,231 | 6,113 | 2,457 | 2,816 |
| Current assets | 22,013 | 10,273 | 13,428 | 11,507 | 11,551 | 9,467 | 5,455 | 4,686 | 1,446 | 1,871 |
| Cash and equivalents | 17,345 | 7,508 | 10,052 | 9,163 | 8,377 | 7,764 | 4,233 | 4,525 | 510 | 1,013 |
| Short-term investments | 887 | 376 | 868 | 7,248 | — | — | — | 72.3 | — | — |
| Receivables | 1,714 | 1,184 | 1,006 | 575 | 976 | 575 | 304 | 21.2 | 49.4 | 15.3 |
| Inventory | 1,302 | 822 | 968 | 1,429 | 1,347 | 706 | 359 | 66.1 | 57.7 | 36.6 |
| Net property, plant and equipment | 5,441 | 5,647 | 4,656 | 3,826 | 3,090 | 1,911 | 1,436 | 1,078 | 762 | 772 |
| Other intangible assets | 1,534 | 1,283 | 27.8 | 30.0 | 19.7 | — | — | — | — | — |
| Long-term investments | 7,860 | 3,901 | 794 | 630 | 417 | 12.9 | 2.0 | — | — | — |
| Current liabilities | 8,387 | 4,369 | 4,477 | 3,499 | 3,050 | 1,486 | 1,044 | 670 | 163 | 76.2 |
| Accounts payable | 495 | 358 | 373 | 326 | 195 | 121 | 84.3 | 42.8 | 34.8 | 21.2 |
| Long-term debt | 1,990 | 2,412 | 2,327 | 2,215 | 2,023 | 925 | 808 | 782 | 3,556 | 3,396 |
| Total debt | 2,816 | 2,831 | 3,621 | 3,229 | 2,497 | 1,207 | 865 | 792 | 3,561 | 3,396 |
| Total liabilities | 17,992 | 8,485 | 8,100 | 6,859 | 5,913 | 3,055 | 2,474 | 1,918 | 4,079 | 3,774 |
| Total equity (incl. minority) | 19,356 | 13,118 | 12,528 | 10,730 | 10,330 | 8,780 | 4,756 | 4,194 | -1,622 | -958 |
| Retained earnings | -15,093 | -15,906 | -15,768 | -14,740 | -12,560 | -9,982 | -8,984 | -7,264 | -1,492 | -930 |
| Minority interest | — | — | — | — | — | — | — | — | 320 | 426 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 41,617 | 37,348 | 23,594 | 21,603 | 20,296 | 20,627 | 17,897 | 17,589 | 16,159 | 16,244 |
| Current assets | 25,006 | 22,013 | 13,093 | 10,273 | 11,049 | 13,428 | 11,385 | 11,507 | 11,195 | 11,551 |
| Cash and equivalents | 17,380 | 17,345 | 9,540 | 7,508 | 8,165 | 10,052 | 7,656 | 9,163 | 8,318 | 8,377 |
| Short-term investments | 832 | 887 | — | 376 | — | 868 | — | — | — | — |
| Receivables | 1,903 | 1,714 | 1,722 | 1,184 | 1,369 | 1,006 | 1,019 | 575 | 1,227 | 976 |
| Inventory | 1,877 | 1,302 | 1,128 | 822 | 690 | 968 | 1,300 | 1,429 | 1,477 | 1,347 |
| Net property, plant and equipment | 5,329 | 5,441 | 5,602 | 5,647 | 5,421 | 4,656 | 4,187 | 3,826 | 3,341 | 3,090 |
| Other intangible assets | 1,468 | 1,534 | 1,388 | 1,283 | 987 | 27.8 | 1,190 | 30.0 | 816 | 19.7 |
| Long-term investments | 1,828 | 7,860 | 3,132 | 3,901 | 2,301 | 794 | 637 | 630 | 397 | 417 |
| Current liabilities | 9,325 | 8,387 | 5,012 | 4,369 | 4,128 | 4,477 | 2,872 | 3,499 | 3,482 | 3,050 |
| Accounts payable | 931 | 495 | 432 | 358 | 221 | 373 | 216 | 326 | 236 | 195 |
| Long-term debt | 1,763 | 1,990 | 2,263 | 2,412 | 2,271 | 2,327 | 2,888 | 2,215 | 1,808 | 2,023 |
| Total debt | 2,323 | 2,816 | 3,379 | 2,831 | 3,349 | 3,621 | 3,452 | 3,229 | 2,766 | 2,497 |
| Total liabilities | 20,871 | 17,992 | 9,172 | 8,485 | 7,869 | 8,100 | 7,114 | 6,859 | 6,568 | 5,913 |
| Total equity (incl. minority) | 20,746 | 19,356 | 14,422 | 13,118 | 12,426 | 12,528 | 10,783 | 10,730 | 9,591 | 10,330 |
| Retained earnings | -13,840 | -15,093 | -15,072 | -15,906 | -16,160 | -15,768 | -14,879 | -14,740 | -13,511 | -12,560 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 10,001 | 1,287 | 148 | -1,919 | -2,025 | -308 | -1,664 | -1,012 | -492 | -363 |
| Depreciation and amortization | 597 | 417 | 310 | 277 | 202 | 85.6 | 86.4 | 62.8 | 59.9 | 53.3 |
| Capital expenditure | -270 | -966 | -1,119 | -897 | -1,066 | -489 | -366 | -313 | -91.0 | -58.4 |
| Investing cash flow | -6,512 | -1,165 | -999 | -1,435 | -2,698 | -5,185 | -2,569 | 855 | -349 | -572 |
| Financing cash flow | 4,728 | -607 | 2,587 | 2,892 | 5,003 | 4,912 | 2,109 | 4,434 | 89.4 | 1,640 |
| Share repurchases | — | — | — | — | — | — | — | — | — | -0.0 |
| Debt issued | 2,504 | 516 | 1,336 | 1,080 | 1,463 | 372 | 43.0 | 287 | 10.0 | — |
| Debt repaid | -2,555 | -1,246 | -949 | -393 | -279 | -33.8 | -19.3 | -5.0 | — | — |
| Effect of exchange rates | -116 | 12.7 | -6.9 | 119 | -197 | -569 | 25.3 | 63.8 | -26.9 | 22.4 |
| Net change in cash | 8,102 | -472 | 1,730 | -343 | 83.2 | -1,150 | -2,099 | 4,341 | -779 | 727 |
| Free cash flow | 9,731 | 321 | -972 | -2,816 | -3,090 | — | — | — | — | — |
| Levered free cash flow | 3,228 | -17.4 | -908 | -2,475 | -2,612 | -806 | -1,622 | -679 | -395 | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3,588 | 9,687 | 314 | 1,503 | -216 | 771 | -623 | -1,112 | -807 | -1,009 |
| Depreciation and amortization | 332 | 331 | 266 | 219 | 199 | 123 | 188 | 152 | 125 | 113 |
| Capital expenditure | -172 | -167 | -103 | -266 | -700 | -521 | -598 | -468 | -429 | -717 |
| Investing cash flow | -8,759 | -7,056 | 545 | -612 | -554 | -1,724 | 725 | -1,815 | 379 | -2,481 |
| Financing cash flow | -497 | 4,080 | 648 | -346 | -261 | 2,343 | 245 | 2,668 | 224 | 500 |
| Debt issued | 362 | 742 | 1,763 | 157 | 359 | 357 | 978 | 549 | 531 | 670 |
| Debt repaid | -856 | -1,340 | -1,215 | -557 | -689 | -192 | -757 | -128 | -265 | -133 |
| Effect of exchange rates | -184 | -106 | -10.0 | 14.3 | -1.6 | 23.9 | -30.7 | -77.5 | 196 | -114 |
| Net change in cash | -5,852 | 6,605 | 1,497 | 559 | -1,032 | 1,413 | 316 | -336 | -7.4 | -3,105 |
| Free cash flow | 3,416 | 9,520 | 211 | 1,237 | -915 | 249 | -1,221 | -1,580 | -1,236 | -1,727 |
| Levered free cash flow | 1,238 | 3,695 | -466 | 652 | -669 | 493 | -1,400 | -1,067 | -1,408 | -1,624 |
Financial statements of similar companies
Companies in the group: same industry, similar size
